In this article, the author analyzes the split of authority that has developed in the lower courts over the preemptive effect of the recent labeling regulations for prescription drugs and suggests that guidance from the appellate courts, and possibly the Supreme Court, is needed.

Source: Tort Trial and Insurance Practice Section of the American Bar Association Spring Newsletter